Saturated fatty acids activate TLR-mediated pro-inflammatory signaling pathways

Shurong Huang¹, Jennifer M. Rutkowsky², Ryan G. Snodgrass³, Kikumi D. Ono-Moore³,
Dina A. Schneider¹, John W. Newman¹, Sean H. Adams¹,³ and Daniel H. Hwang¹,³,*

Western Human Nutrition Research Center, Agricultural Research Service, United States Department of Agriculture¹, Department of Anatomy, Physiology and Cell Biology² and Department of Nutrition³, University of California Davis, CA.

Running title: Fatty acid specific activation of TLR signaling pathways

*Corresponding author:

Daniel H. Hwang, Ph.D.
Western Human Nutrition Research Center, ARS-USDA
430 West Health Science Drive, Davis, CA 95616, U.S.A.
Phone: 530-754-4838
Fax: 530-752-5295
e-mail: daniel.hwang@ars.usda.gov
Authors:

Shurong Huang
Western Human Nutrition Research Center, ARS-USDA,
430 West Health Science Drive, Davis, CA 95616, USA.
Phone: (530) 752-7376
Fax: (530) 752-5295
Email: Shurong.huang@ars.usda.gov

Jennifer M. Rutkowsky
Department of Anatomy, Physiology and Cell Biology, University of California,
One Shields Ave., Davis, CA 95616, USA.
Phone: (530) 752-7376
Fax: (530) 752-5295
Email: jrutkowsky@ucdavis.edu

Ryan G. Snodgrass
Department of Nutrition, University of California
One Shields Ave., Davis, CA 95616, USA.
Phone: (530) 752-7376
Fax: (530) 752-5295
Email: rgsnodgrass@ucdavis.edu

Kikumi D. Ono-Moore
Department of Nutrition, University of California
One Shields Ave., Davis, CA 95616, USA.
Phone: (530) 752-7376
Fax: (530) 752-5295
Email: kdonomoore@ucdavis.edu

Dina A. Schneider
Western Human Nutrition Research Center, ARS-USDA
430 West Health Science Drive, Davis, CA 95616, USA.
Phone: (530) 752-7376
Fax: (530) 752-5295
Email: daschneider@ucdavis.edu

John W. Newman
Western Human Nutrition Research Center, ARS-USDA,
430 West Health Science Drive, Davis, CA 95616, USA.
Phone: (530) 752-6571
Fax: (530) 752-5295
Email: john.newman@ars.usda.gov
ABSTRACT

Toll-like receptor 4 (TLR4) and TLR2 were shown to be activated by saturated fatty acids (SFAs) but inhibited by docosahexaenoic acid (DHA). However, one report suggested that SFA-induced TLR activation in cell culture systems is due to contaminants in BSA used for solubilizing fatty acids. This report raised doubt about proinflammatory effects of SFAs. Our studies herein demonstrate that sodium palmitate (C16:0) or laurate (C12:0) without BSA solubilization induced phosphorylation of IκBα, JNK, ERK, and NFκB subunit p65, and TLR target gene expression in THP1 monocytes or RAW264.7 macrophages, respectively when cultured in low FBS (0.25%) medium. C12:0 induced NFκB activation through TLR2 dimerized with TLR1 or TLR6, and through TLR4. Since BSA was not used in these experiments, contaminants in BSA have no relevance. Unlike in suspension cells (THP-1), BSA-solubilized C16:0 instead of sodium C16:0 is required to induce TLR target gene expression in adherent cells (RAW264.7). C16:0-BSA transactivated TLR2 dimerized with TLR1 or TLR6, and through TLR4 as seen with C12:0. These results and additional studies with the LPS sequester polymixin B and in MyD88-/- macrophages indicated that SFA-induced activation of TLR2 or TLR4 is a fatty acid-specific effect, but not due to contaminants in BSA or fatty acid preparations.

Supplementary key words: saturated fatty acids, docosahexaenoic acid, Toll-like receptors, reactive oxygen species

Abbreviations: PAMP, pathogen-associated molecular pattern; DAMP, endogenous damage associated molecular patterns; TLRs, Toll-like receptors; PRR, pattern recognition receptors;
NOD, nucleotide-binding oligomerization domain family; MDP, muramyldipeptide MurNAc-L-Ala-D-isoGln; NF-κB, nuclear factor-κB; IκB, inhibitor of NF-κB.
INTRODUCTION

Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain protein (NODs) like receptors (NLRs) detect invading pathogens by recognizing conserved pathogen-associated molecular patterns (PAMPs) and activate innate immune responses for host defense. However, PRRs can be activated by a wide variety of endogenous damage associated molecular patterns (DAMPs) derived from tissue injury or stress, and induce sterile inflammation to initiate wound healing processes. Emerging evidence suggests that PRRs can also sense metabolic disturbance and link immune responses to metabolic homeostasis (1, 2). Such a functional diversity of PRRs may be achieved by their ability to recognize a wide variety of structurally unrelated molecules. However, such a broad specificity of PRRs in recognizing agonists can make them susceptible to dysregulation leading to development of chronic inflammation, which in turn can promote development and progression of many chronic diseases including atherosclerosis, insulin resistance, Alzheimer’s disease and cancer. Recent studies revealed that dietary components and metabolic intermediates can alter the activity and the expression of PRRs suggesting that PRR-mediated inflammation and its functional consequence are dynamically modulated by what we eat (3, 4).

High saturated fat diets have been used for diet-induced obesity and insulin resistance in many animal studies. Both in vitro and in vivo studies suggest that saturated fatty acids (SFAs) can activate pro-inflammatory signaling pathways leading to insulin resistance (5). The molecular mechanism by which SFAs activate pro-inflammatory signaling pathways remains obscure. Our previous studies revealed that saturated fatty acids activate but n-3 polyunsaturated fatty acid (PUFA) DHA inhibits TLR4- and TLR2-mediated signaling pathways leading to expression of
pro-inflammatory marker gene products (6-9). Numerous studies with cells in culture and in animal models of mutated or deleted TLR4 or TLR2 subsequently demonstrated that saturated fatty acids indeed can activate TLR4- and TLR2-mediated pro-inflammatory signaling pathways and consequently, increase risk of insulin resistance (10-19). However, one report (20) suggested that SFA-induced TLR activation is due to contaminants in bovine serum albumin (BSA) used for solubilizing fatty acids. This report casted doubt upon the pro-inflammatory effects of SFAs.

TLRs are activated by various microbial components (i.e. endotoxins) that are ubiquitously present in our environment. Therefore, potential contamination of microbial components in reagents used for in vitro and in vivo studies is not a trivial technical issue for investigations focusing on the role of endogenous molecules in modulating TLRs and other PRRs. Such caution is particularly important if the testing materials are prepared in recombinant bacterial systems. This issue was exemplified in the controversy regarding whether the activation of TLR4 by HSP60 prepared as a bacterial recombinant protein is a bona fide effect of HSP60 or due to bacterial contaminants (21, 22).

Unfortunately, commercial assay kits for the detection of endotoxin (TLR4 ligand) are unable to detect other microbial ligands which active TLRs other than TLR4. Therefore, we used cell-based biological assays to assess potential contamination of TLR agonists in reagents. In this report, multiple lines of evidence are presented that the activation of TLR-mediated proinflammatory signaling pathways by SFAs is a fatty acid-specific effect and not due to contaminants in the reagents. Experimental conditions optimizing responsiveness of cells to
fatty acids revealed further mechanistic insight that the responsiveness of cells to TLR agonists is largely dependent on the tone of reactive oxygen species in cell culture systems.

METHODS

Reagents. LPS (Cat #: 421), Pam3CSK4 (Cat #: tlrl-pms) and MDP (Cat #: G-1055) were purchased from List Biological Laboratories, Inc. (Campbell, CA), Invivogen (San Diego, CA) and BACHEM Bioscience Inc. (King of Prussia, PA), respectively. Endotoxin free water, polymixin B and antibody for β-actin were purchased from Sigma (Saint Louis, MO). Antibodies for JNK (Cat #: 9252), phospho-JNK (Cat #: 9251), ERK (Cat #: 9102), phospho-ERK (Cat #: 9101), phospho-IκBα (Cat#: 2859), NFκB p65 (Cat#: 3034) and phospho-NFκB p65 (Cat#: 3033) were purchased from Cell Signaling Technology (Danvers, MA). IκBα antibody (Cat#: SC-371) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal anti-COX-2 immune serum was prepared using a synthetic COX-2 polypeptide as immunogen. Fetal bovine sera (FBS) were purchased as follows: premium select FBS (Catalog #: S11595 and S11550, Lot #: K0109) and Optima FBS (Catalog #: S12495, Lot #: L0019) from Atlanta Biologicals (Lawrenceville, GA), Hyclone FBS (Catalog #: SH30071, Lot #: ATD31956) from HyClone (Logan, UT), Gibco FBS (Catalog #: 10082, Lot #: 544122) from Invitrogen (Carlsbad, CA), and Atlas FBS (Catalog #: F-0500-A, Lot #: 80814) from Atlas Biologicals (Fort Collins, CO). Bovine serum albumin (BSA, Cat #: 30-AB79, Lot #: A10072001) was purchased from Fitzgerald Industries International (Acton, MA). Sodium laurate was purchased from Nu-Chek Prep (Elysian, MN). Palmitic acid (Cat #: P5585, Lot #:020M15811), sodium palmitate (Cat #: P9767, Lot # 079K1444), sodium salt docosahexaenoic acid (DHA) (Cat #: D8768, Lot #: 077K5215) and BSA (Catalog #: A8806, Lot #: 118K7405,
040M7715 and 034K7605) were purchased from Sigma (Saint Louis, MO). Apocynin (Cat #: 178385) was purchased from EMD Chemicals (Gibbstown, NJ). TLR4 inhibitor TAK-242 (Cat #: tlrl-cli95) was obtained from Invivogen (San Diego, CA).

**Cell culture.** RAW264.7 (murine monocytic cell line), purchased from ATCC (Manassas, VA), immortalized MyD88-/- macrophages (provided by Dr. Kate Fitzgerald, University of Massachusetts) and HEK293T (human embryonic kidney epithelial cell line provided by Sam Lee, Beth Israel Hospital, MA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % (v/v) FBS (premium select FBS, Catalog #: S11550, Lot #: K0109, Atlanta Biologicals, Lawrenceville, GA), 100 units/ml penicillin, and 100 µg/ml streptomycin. THP-1 cells (human monocytic cell line, ATCC TIB-202) were cultured in RPMI-1640 medium containing 10% (v/v) FBS, 0.05 mM 2-mercaptoethanol, 100 units/ml penicillin, and 100 µg/ml streptomycin. The immortalized MyD88-/- macrophages were originally prepared using bone marrow-derived macrophages from MyD88-/- mice with J2 recombinant retrovirus (23). All cell cultures were maintained at 37 °C in a 5% CO₂ atmosphere.

**Plasmids.** Expression vectors pDisplay, pDisplay-TLR1, pDisplay-TLR2, pDisplay-TLR3, pDisplay-TLR4, pDisplay-TLR5 and pDisplay-TLR6 were obtained from Adeline Hajjar (University of Washington, Seattle, WA). MD2 was provided by Kensuke Miyake (Tokyo Univ., Japan). (2x)-NF-kB-luciferase reporter construct was provided by Frank Mercurio (Signal Pharmaceuticals, San Diego, CA). pRSV-β-galatosidase plasmid was from Jongdae Lee (University of California, San Diego, CA). The plasmid DNA from these expression vectors was
prepared in large scale for transfection using the EndoFree Plasmid Maxi kit (Qiagen, Valencia, CA).

**Transfections and luciferase assays.** Transient transfections were carried out using SuperFect transfection reagent (Qiagen, Valencia, CA) according to the manufacturers’ recommendations. HEK293T cells were seeded at 2 x 10^5 per well of 24-well plates and co-transfected the following day with 10 ng each of pDisplay-TLR4 and MD2, or pDisplay-TLR2 and pDisplay-TLR1, or pDisplay-TLR2 and pDisplay-TLR6, in addition to 50 ng (2x)-NF-κB-luciferase reporter and 10 ng pRSV-β-galactosidase expression vectors. Twenty nanograms (20ng) of pDisplay empty vector was used in addition to the above amounts of (2x)-NF-kB and pRSV-b-galactosidase for transfection as controls. 24 hr after transfection the cells were serum starved in 0.25% FBS/DMEM medium for 6 hr followed by 12 hr treatment with fatty acids in the same low serum medium. The cells were lysed. Luciferase and β-galactosidase enzyme activities were determined from the lysate supernatants using the luciferase and β-galactosidase enzyme assay system (Promega, Madison, WI) according to the manufacturer’s instructions. Luciferase activity was normalized by β-galactosidase activity to correct differences in transfection efficiency among samples. Each of the experiments was repeated at least three times.

**BSA solubilization of palmitic acid.** Palmitic acid (C16:0) is water insoluble and needs to be complexed with BSA to solublize. The solubilization process was carried out as previously described (24) with modifications. Briefly, C16:0 was dissolved in 100 % ethanol (250mM or 500mM) then mixed with BSA in a 10:1 molar ratio in 0.25% FBS/DMEM or 0.25% FBS/RPMI medium. The mixture was sonicated in a water bath for 15 min followed by incubation on a
Shaker in an oven at 55°C for 15 min. The solubilized C16:0 was filtered through a 0.22 μm filter before use.

**Solubilization of sodium salt FA.** A stock solution of 100mM C12 sodium salt was prepared in endotoxin free water. A stock solution of 100mM C16 sodium salt was prepared in 70% ethanol in a glass vial and heated to 60°C. C16 sodium salt was reheated to 60°C and quickly vortexed before cells were treated to give appropriate final concentration indicated in figures. A stock solution of 10mM DHA sodium salt was prepared in endotoxin free water, flushed with nitrogen, then sealed in air tight tube and stored at -20°C until use.

**Immunoblot and ELISA assays.** RAW 264.7 and MyD88-/- macrophage cells were seeded at 1.2-1.5 x 10^6 per well of 6-well plates. The next day the cells were serum starved in 0.25% FBS/DMEM medium for 6 hr and then treated with fatty acids in the same low serum medium. THP-1 cells were seeded at 1 x 10^6 cells/ml in T-25 flasks and serum starved in 0.25% FBS/PRMI medium for 12 hr. The cells were then treated with fatty acids in the same low serum medium as indicated in the figure legend. After the treatments the medium supernatants were collected. The cells were rinsed with cold PBS twice and then lysed by sonication in cell lysis buffer (Cell Signaling Technology, Danvers, MA) containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na₂EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na₃VO₄, and 1 μg/ml leupeptin. The lysate supernatants were collected by centrifugation and subjected to 10% SDS-PAGE followed by transfer of the proteins to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). The membrane was blocked in TBST buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.05% (v/v) Tween 20) containing...
5% non-fat milk. The membrane was probed with primary antibody for 1 hr at room temperature or overnight at 4 °C followed by incubation with horse radish peroxidase-conjugated secondary antibody (Amersham Biosciences, Piscataway, NJ) for 1 h at room temperature. The proteins were detected by the ECL Western blot detection reagents (Amersham Biosciences, Piscataway, NJ) followed by exposure to an X-ray film (BioExpress, Kaysville, UT). Enzyme-linked immunosorbent assays (ELISA) were carried out for TNF-α and IL-8 in the cell culture medium supernatants using a TNF-α ELISA kit (eBioscience, San Diego, CA) and an IL-8 ELISA kit (BD Biosciences, San Diego, CA), respectively, and a Synergy 2 plate reader (BioTek, Winooski, VT) following the manufacturers’ instructions.

**ROS analysis.** RAW264.7 cells were seeded at 1 x 10^6 per well of 6-well plates in 10% FBS/DMEM medium. The next day the cells were serum starved in 0.25% FBS/DMEM for 6 hr followed by treatment with 0.2 ng/ml LPS, 100 μM C12:0, 50 μM BSA, or 500 μM BSA-solubilized C16:0 for 18 hr. The cells were washed two times with warm PBS and stained with 5 μM 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) for 30 min. The stained cells were washed with cold PBS three times and resuspended by scraping in PBS containing 2% FBS. The levels of ROS production were determined from the gated living cells by flow cytometry with a laser excitation at 488 nm using a FACSCalibur flow cytometer (BD Biosciences, Sparks, MD). The levels of ROS production were also examined by confocal microscopy. Briefly, RAW 264.7 cells were seeded at 1 x 10^5 onto a coverglass placed in a well of 24-well plates in DMEM medium containing 10% FBS. The cells were serum starved for 6 hr and then treated with 10 μM CM-H2DCFDA in PBS for 30 min at 37 °C. After washing three times with warm PBS, the cells were treated with 100 ng/ml
LPS, 150 µM lauric acid, 50 µM BSA or 500 µM BSA-solubilized C16:0 for 30 min in 0.25% FBS/DMEM. The cells were washed with cold PBS three times, fixed in 10% formalin for 30 min at 4 °C and washed again with cold PBS three times. The coverglasses were then mounted on glass slides. Confocal microscopy was performed with a Zeiss LSM 510 microscope with 40x1.3 oil objective lens using laser excitation at 488 nm.

**LAL assay.** The LAL (Limulus Amebocyte Lysate) assays were carried out using a recombinant factor C endotoxin detection system (Lonza, Walkersville, MD) following the manufacturers’ instructions. A 100 µl sample was mixed with 100 µl substrate/enzyme reagents and incubated at 37 °C for 1 hr. The resulting fluorescence was measured at 380 nm/440 nm. The LAL assays were also carried out using a ToxinSensor chromogenic LAL endotoxin assay kit (GeneScript, Piscataway, NJ) following the manufacturer’s instructions. Briefly, 25 µl of samples were mixed with 25 µl LAL lysate and incubated at room temperature for 5 min. 25 µl of chromogenic substrate was then added to each of the reactions and incubated at 37 °C for 5 min (for high endotoxin samples) or 30 min (for low endotoxin samples). The reactions were terminated by adding 125 µl each of the three color stabilizer solutions. The endotoxin levels were then measured by spectrophotometry at 545 nm using a Synergy 2 plate reader (BioTek, Winooski, VT) following the manufacturers’ instructions. The endotoxin concentrations of the samples were calculated from the standard curve obtained using the endotoxin standards provided by the kits.
**Data analysis.** Each of the experiments was repeated at least three times. Data from the reporter, ELISA and ROS assays presented as mean±SEM were analyzed by a 2-tailed Student *t*-test.

**RESULTS**

**Induction of TLR-mediated target gene expression by saturated fatty acids.** Our previous studies demonstrated that water-soluble sodium laurate (C12:0) (without BSA solubilization) activates PRRs (TLR2, TLR4, NODs) (7, 25). Therefore, potential contamination of PRR agonists in BSA was not an issue. Consistent with our previous results, treatment of RAW 264.7 cells with sodium laurate (C12:0) led to induction of COX-2 and TNF-α expression (Fig. 1 A, B). However, palmitic acid (C16:0) is insoluble in aqueous solution and requires to be complexed with BSA to solubilize. To determine whether C16:0-induced expression of PRR target genes (COX-2, TNF-α) is attributed to contaminants in BSA, we treated RAW 264.7 cells with BSA alone or BSA-solubilized C16:0 (C16:0-BSA). Similar to sodium salt C12:0, C16:0-BSA induced COX-2 and TNF-α expression whereas BSA alone at equivalent concentrations used to solubilize C16:0 had no effect (Fig. 1 A, C). Next, we determined whether C12:0 or C16:0-BSA-induced expression of COX-2 or TNF-α is due to contamination of LPS in BSA or fatty acid preparations. The LPS sequestering agent polymixin B did not attenuate C12:0 or C16:0-BSA-induced COX-2 and TNF-α expression indicating that the effects of the saturated fatty acids are not due to LPS contamination in BSA or fatty acid preparations (Fig. 2).

Erridge and Samani (20) suggested that SFA-induced cytokine expression in RAW 264.7 cells is due to contaminants present in BSA or fatty acid preparations that can activate TLR2. If that is the case, C12:0- or C16:0-BSA-induced COX-2 or TNF-α expression should be abolished in
MyD88-/− macrophages because TLR2 activates exclusively MyD88-dependent downstream signaling pathways. Therefore, we determined whether C12:0- or C16:0-BSA induced COX-2 or TNF-α expression is abolished in MyD88-/− macrophages. The results showed that C12:0 or C16:0-BSA still induced COX-2 and TNF-α expression in MyD88-/− macrophages (Fig. 3) eliminating the possibility that the induction of COX-2 or TNF-α expression by C12:0 or C16:0-BSA is due to contaminants in BSA or fatty acid preparations that can activate TLR2 or other MyD88-dependent TLRs or IL-1β receptor. Many studies have shown that saturated fatty acids can activate TLR4, TLR2 and NODs in macrophages (6, 7, 10, 13, 25). TLR4 activates both MyD88-dependent and independent pathways, and MyD88 is not the downstream component of NODs. Thus, saturated fatty acids should still induce the expression of COX-2 or TNF-α in MyD88-/− cells as shown in Fig. 3. Additional evidence that pro-inflammatory effects of saturated fatty acids are not due to the potential contaminants in the reagents in in vitro systems is that while saturated fatty acids activate TLR-mediated pro-inflammatory signaling pathways, polyunsaturated fatty acids particularly n-3 fatty acid DHA inhibits saturated fatty acid-induced activation of TLR-mediated pro-inflammatory signaling pathways (3, 6-8). Similarly, C12:0 induced phosphorylation of ERK and JNK but DHA inhibited C12:0-induced ERK phosphorylation and COX-2 expression (Fig. 4). When MyD88-/− cells were treated with fatty acids in the presence of polymixin B (LPS sequester), C12:0 or C16:0-BSA (Fitzgerald BSA) still induced COX-2 and TNF-α expression (Fig 3). Under this condition, any effects of LPS and other contaminants that can activate MyD88 dependent TLRs are eliminated.

It should be noted that we have screened several commercially available BSA preparations for the presence of potential contaminants that can induce the expression of TLR or other PRR target
gene products in RAW264.7 cells. Some commercially available BSA preparations induced the expression of TLR target gene product COX-2 (Supplemental Fig.1) suggesting the presence of contaminants that can activate TLR or other PRRs in these BSA preparations. BSA-1 (Sigma Cat #: 8806, Lot 118K7405), BSA-2 (Sigma Catalog #: A8806, Lot 040M7715V) and BSA-3 (Sigma Catalog #: A8806, Lot 034K7605) which induced COX-2 expression in RAW264.7 cells even in the presence of polymixin B (Supplement Fig. 1A, C, E), did not induce COX-2 expression in MyD88-/- cells (Supplemental Fig. 1B, D, F) suggesting that the contaminants in these BSA preparations are compounds that can activate primarily TLR2 or other MyD88-dependent pro-inflammatory pathways. Taken together, these results demonstrate that fatty acid-induced COX-2 or TNF-α expression is not due to LPS or other contaminants that can activate TLR2 or other MyD88-dependent TLRs in BSA or fatty acid preparations.

LAL assays showed that these BSA preparations contained significant levels of endotoxins (Supplemental Table 1). Among these BSA preparations tested, the one from Fitzgerald Industries International (Acton, MA, Cat #: 30-AB79, Lot #: A10072001) alone did not show significant induction of COX-2 and TNF-α expression (Fig.1). An LAL assay also showed that this BSA preparation contained undetectable level of endotoxin (Supplemental Table 1). Therefore, this BSA preparation was used throughout the current studies. In addition, the responsiveness of RAW264.7 cells to SFAs varied significantly with the source of FBS (Supplemental Fig. 2). This variation in the responsiveness of RAW264.7 cells to C12:0 was not correlated with the fatty acid composition of lipids in FBS (data not shown).
Activation of PRR signaling pathways by saturated fatty acids. Sodium laurate (C12:0) without BSA solubilization activated the downstream signaling pathways of TLRs in adherent RAW 264.7 cells, leading to increased phosphorylation of JNK and ERK (Fig. 4A). C12:0-induced ERK phosphorylation was attenuated by DHA (Fig. 4B), leading to suppression of C12:0-induced COX-2 expression (Fig. 4C). Treatment of THP-1 cells (a monocytic suspension cell line) with sodium palmitate (C16:0) without BSA solubilization activated the downstream signaling pathways of TLRs, leading to enhanced phosphorylation of JNK, IκBα and NFκB subunit p65 (Fig. 4D). The activation of the TLR pathways by C16:0 led to enhanced expression of IL-8 (Fig. 4E). Similar to C12:0, C16:0-induced IL-8 expression was also suppressed by DHA (Fig. 4F) whereas polymixin B had no effect (Fig. 4E). In addition, C16:0-BSA but not BSA alone also strongly induced JNK phosphorylation and IL-8 expression in THP-1 cells (Supplemental Fig. 3). IL-8 expression induced by C16:0-BSA was inhibited by DHA but was not affected by polymixin B treatment (Supplemental Fig. 3). Since BSA was not used in studies with sodium laurate and sodium palmitate, potential contaminants in BSA preparation that can activate PRRs are not an issue. C12:0 transactivated NFκB mediated through TLR2 dimerized with TLR1 or TLR6, or through TLR4 (Fig. 5 A-C). Similarly, C16:0-BSA also induced NFκB activation mediated through these TLRs (Fig. 5 D-F). Taken together, these results indicate that saturated fatty acid-induced activation of downstream signaling pathways of TLR4 and TLR2 is the specific effect of saturated fatty acids, and not due to potential contaminants in fatty acid or BSA preparations.

Production of reactive oxygen species (ROS) is increased in cells cultured in a serum poor medium, and leads to enhanced propensity of cells to be activated by saturated fatty acids.
In our previous studies demonstrating that saturated fatty acids activate TLR2 and TLR4, cells were cultured in the serum poor (0.25% FBS) medium. Thus, we examined how the responsiveness of cells to C12:0 or TLR agonists is affected by different serum concentrations in the culture media. The responsiveness of RAW 264.7 cells to C12:0, C16:0-BSA or TLR agonists (LPS, a TLR4 agonist; Pam3CSK4, a TLR2 agonist) was greatly potentiated when the cells were cultured in the serum poor (0.25%) medium compared to the cells cultured in 10% FBS (Fig. 6). The induction of COX-2 expression by C12:0 was almost completely abolished in the cells cultured in the medium with 10% FBS (Fig 6A). Similar results were obtained with C16:0-BSA (Fig. 6B). The activation of TNF-α expression by LPS, C12:0 or C16:0-BSA was also significantly increased in cells cultured in the low serum (0.25%) medium compared to cells cultured in the high serum (10%) medium (Fig. 6C). It should be noted that the results reported by Erridge and Samani (20) showing that sodium laurate did not induce TNF-α expression or IκBα degradation were obtained in RAW 264.7 cells cultured in the medium with 10% FCS.

We further investigated what might contribute to the enhanced responsiveness of cells to fatty acids in the serum poor medium. The production of reactive oxygen species (ROS) has been shown to be increased by serum deprivation in HEK293 or neuronal cells in culture (26-28). Ligand-induced activation of TLR4 requires recruitment of the receptor into lipid rafts in a ROS-dependent manner (29, 30). Our previous studies demonstrated that C12:0 induces dimerization and recruitment of TLR4 into lipid rafts in a ROS-dependent manner (8). Activation of TLR2 was also shown to stimulate the activity of NADPH oxidase (31, 32). Together, these results suggest that the responsiveness of cells to TLR4 agonists depends in part on ROS tone of cells in culture. Therefore, we examined the ROS levels in the cells cultured in the medium with high
(10%) or low (0.25%) FBS concentrations. As shown in Fig. 6D, E, ROS production in vehicle control, LPS-, C12:0-, BSA- or C16:0-BSA-treated cells was significantly increased by the culture medium with 0.25% FBS compared to that with 10% FBS, suggesting that ROS potentiates the agonist effects of saturated fatty acids. Consequently, C12:0-induced phosphorylation of JNK and ERK was significantly enhanced if the cells were cultured in low FBS (0.25%) compared to 10% FBS (Fig. 6F). These results suggest that low serum in culture medium increases ROS production, which, in turn, enhances the responsiveness of cells to LPS or saturated fatty acids in activating TLR-mediated signaling pathways. Consistent with this notion, treatment of RAW264.7 cells with sodium salt C12:0 or C16:0-BSA in the low serum medium led to increased ROS production (Fig. 7A). An inhibitor of NADPH oxidase, apocynin, suppressed the enhanced phosphorylation of JNK and ERK, and the expression of COX-2 and TNF-α induced by C12:0 or C16:0-BSA in the low serum medium (Fig. 7B-G). Taken together, these results demonstrate that ROS tone in cells in culture is one of the key conditions that can modulate the responsiveness of the cells to saturated fatty acids.

Discussion

Our results presented here demonstrate that saturated fatty acids without being bound to BSA can activate TLR-mediated pro-inflammatory signaling pathways in macrophages (RAW264.7) and monocytes (THP-1) in a low serum culture medium. However, DHA inhibits saturated fatty acid-induced activation of TLR-mediated signaling pathways. These results indicate that saturated fatty acid-induced activation of TLR-mediated signaling pathways and target gene expression is not due to contaminants in BSA or fatty acid preparations. The results from LAL assays also showed that the fatty acids and other reagents used in these studies contained trace or
undetectable amounts of endotoxins (Supplemental Table 1). LAL assay showed that sodium palmitate at 150 µM and palmitic acid at 500 µM (the maximum concentrations used in these studies) contain trace amounts of endotoxin (0.064 EU/ml and 0.046 EU/ml endotoxin, respectively; Supplemental Table 1), which is equivalent to 18 pg/ml LPS and 16 pg/ml LPS, respectively, as determined from the LPS titration standard curve (Supplemental Fig. 4). However, endotoxin levels in both sodium palmitate and palmitic acid as measured by LAL assay did not show a dose dependent pattern (Supplemental Fig. 4) suggesting that LAL readings for palmitic acid may reflect assay interference caused by palmitic acid. It should be noted that a majority of the substances tested for endotoxin either, inhibit or enhance the LAL test to some degree (33). Therefore, we have developed cell-based assays to assess endotoxin and other contaminants in our experimental reagents that can activate TLR2 or TLR4. In MyD88-/- cell in the presence of polymixin B, any effects of endotoxin and potential contaminants that can activate TLR2 and other MyD88-dependent TLRs are eliminated. Therefore, if the activation of TLR2 or TLR4 by saturated fatty acids is due to contaminants that can activate TLR2 or TLR4, the saturated fatty acids should not be able to induce the expression of TLR target gene products in MyD88-/- cells in the presence of polymixin B. The fact that the saturated fatty acids still induce the expression of the TLR target gene products under this condition (Fig. 3) indicates that the activation of TLR2 or TLR4 by the saturated fatty acids is not due to the presence of potential contaminants that can activate TLR2 or TLR4. Furthermore, even if we accept the trace amounts of endotoxin in palmitate as measured by LAL assay as valid, these levels of endotoxin (16-18 pg/ml LPS) in palmitate cannot account for the expression of COX-2, TNF-α or IL-8 (Supplemental Fig. 5) induced by palmitate. In addition, DHA inhibited LPS- or saturated fatty acid-induced TLR target gene expression, whereas C12:0 or C16:0 consistently
showed stimulatory effects on TLR activation in our studies (Fig. 4, Supplemental Fig. 3C and 6). As these fatty acids are prepared in an identical manner in the laboratory, it is highly improbable that saturated fatty acids are contaminated with something that can stimulate TLR activation, whereas DHA is contaminated with something that can inhibit TLR activation. Thus, these results further counter the speculation that the stimulatory effects of SFAs may be due to contaminants in fatty acid preparations. Furthermore, a pharmacological inhibitor (TAK-242) of TLR4 suppressed both LPS- and C12:0-induced COX-2 and TNF-α expression, suggesting that C12:0-induced activation of COX-2 and TNF-α expression is in part mediated through TLR4 signaling pathway (Supplemental. Fig. 7). Our previous studies also showed that C12:0 induces dimerization and recruitment of TLR4 into lipid rafts (8).

The responsiveness of cells to saturated fatty acids is greatly potentiated in the culture medium with low FBS concentration (0.25%) compared to the culture medium with 10% FBS, which is correlated with enhanced ROS production by the cells cultured in the low serum medium. These results provide mechanistic insight about the activation of TLR-derived signaling pathways induced by saturated fatty acids, and further suggest that conditions that modulate ROS tone can affect the responsiveness of cells to saturated fatty acids in activating TLR-derived signaling pathways and its functional consequences.

How saturated fatty acids can activate TLR2 and TLR4 is an intriguing question. Ligand binding, receptor dimerization, translocation of the receptor into lipid rafts, and recruitment of the immediate downstream signaling molecules are the potential steps through which fatty acids can modulate activation of these receptors. The Lipid A moiety in LPS is acylated by medium-
chain (C12-C14) saturated fatty acids (SFAs) (34). Removal of these saturated fatty acids from Lipid A results in complete loss of endotoxic activity (35). Lipid A acylated by unsaturated fatty acids instead of saturated fatty acids is nontoxic and acts as an antagonist against the wild type endotoxin (36-38). Bacterial lipopeptides that activate TLR2 are also acylated by SFAs. These results suggest that the fatty acids acylated in lipid A or bacterial lipoproteins play a critical role in receptor activation for TLR2 and TLR4. The crystal structure for TLR4-MD2-LPS complex revealed that five out of six fatty acyl groups in LPS are completely buried inside the large hydrophobic ligand binding pocket in MD2 (39). Binding of LPS to MD2 induces dimerization with TLR4 through both hydrophobic and hydrophilic interaction mediated by the fatty acyl groups and two phosphate groups in Lipid A, respectively. It is an intriguing question whether free fatty acids (without the polar head group of Lipid A) resembling the saturated fatty acids acylated in Lipid A can still interact with the hydrophobic ligand binding site of MD2 and promotes dimerization of TLR4 with MD2 or MyD88.

The X-ray crystal structure for TLR1-TLR2 heterodimer revealed that two ester-bound fatty acyl chains of tri-acylated lipopeptide (Pam₃CSK₄) are inserted into the hydrophobic ligand binding pocket in TLR2, while the amide-bound fatty acyl group is inserted into a hydrophobic channel in TLR1 (40). Thus, binding of fatty acyl groups of Pam₃CSK₄ into TLR2 induces heterodimerization of TLR1-TLR2. It is again an interesting question whether saturated free fatty acids resembling the fatty acids in the lipopeptides can interact with the ligand binding site in TLR2 or TLR1 and promote the dimerization of the receptors or the dimerization of the receptors with the immediate downstream adaptor MyD88 through TIR domains. TLR2 and TLR1 or TLR6 can dimerize in a ligand independent manner when they are over expressed (41).
Interestingly, it was shown that saturated fatty acid lauric acid can activate TLR4 and TLR2 dimerized with TLR1 or TLR6 but no other TLRs (6, 7). The X-ray crystal structure and sequence analysis indicated the presence of the lipid binding hydrophobic pocket or channel in MD2 or LRR domains of TLR1, TLR2, TLR4 and TLR6 but not in other TLRs (42). No ligands for TLRs other than TLR4 and TLR2 are known to be acylated by SFAs. While the detailed molecular interaction between LPS or lipopeptides, and TLR4 or TLR2, respectively has been revealed using truncated receptors without cytoplasmic domains, potential ligand activity of various endogenous molecules containing fatty acyl chains remains to be determined.

Activation of TLR4 requires translocation of the receptor into lipid rafts within plasma membrane where it recruits downstream signaling molecules such as MyD88 and NADPH oxidase for the activation of downstream signaling pathways (8, 29, 30). Lipid rafts are liquid-ordered phase microdomains of plasma membrane which serve as signaling platform to concentrate receptors, co-receptors, adaptors and down-stream signaling molecules to promote the transmission of extracellular signals to intracellular signaling pathways. Lipid rafts have a special lipid composition that is rich in cholesterol, sphingolipids and glycolipids. The polar lipids in lipid rafts are predominantly acylated by SFAs unlike phospholipids in non-lipid raft membranes, which are acylated by polyunsaturated fatty acids suggesting that saturated fatty acyl chains favor lipid raft association. Both TLR4 and TLR2 ligands LPS and lipopeptides, respectively, are acylated by SFAs. An emerging paradigm for the regulation of lipid raft formation suggests that clustering of molecules with high affinity for lipid rafts (raftophilicity) can greatly increase the size and stability of lipid rafts (43). It was shown that SFA lauric acid
induces but n-3 PUFA docosahexaenoic acid (DHA) inhibits dimerization and recruitment of TLR4 into lipid rafts in macrophages (RAW264.7) (8).

Another possible mechanism by which SFAs activate TLR2 and TLR4 includes palmitoylation (acylation) of endogenous signaling molecules or enhanced synthesis of complex lipids that can interact with ligand binding domains. However, no experimental evidence has been reported to support this hypothesis.

Summary

The results presented here demonstrate that saturated fatty acids induced activation of TLR2 and TLR4 is fatty acid specific effects but not due to contaminants in reagents. TLRs are involved not only in host defense but also wound healing and possibly linking metabolic disturbance to immune responses. Such diverse tasks of TLRs can be fulfilled by recognizing a variety of endogenous molecules. While the detailed molecular interaction between TLR4 or TLR2 and their respective ligands (i.e. LPS and lipopetides) has been revealed by X-ray crystallographic studies using truncated receptors without cytoplasmic domains, the potential ligand activity of a variety of endogenous molecules containing fatty acyl chains remains to be determined. Revelation of the mechanism by which such endogenous molecules activate TLR-mediated signaling pathways will greatly advance our understanding how TLR-mediated sterile inflammation is associated with the development and progression of many chronic diseases.
Acknowledgments. This work was supported by grants from NIH R01 (DK064007, DK41868, DK078328S) and program funds from the Western Human Nutrition Research Center/ARS/USDA (5306-51530-017-00D and 5306-51530-019-00). USDA is an equal opportunity employer and provider.
REFERENCES


FIGURE LEGENDS

Fig. 1. Sodium laurate (C12:0) and BSA-complexed palmitic acid (C16:0-BSA), but not BSA alone induced the expression of proinflammatory TLR target gene products COX-2 and TNF-α. RAW 264.7 cells were serum starved (0.25% FBS) for 6 hr in DMEM medium and then treated with C12:0, C16:0-BSA, or equivalent concentrations of BSA in the same low serum medium for 18 hr. The protein lysates were probed with anti-COX-2 or anti-β-actin antibody by immunobloting (A). Culture medium supernatants were assayed for TNF-α by ELISA (B, C). Controls: LPS (TLR4 agonist, 0.2 ng/ml), Pam (Pam3CSK4, TLR2 agonist, 2 ng/ml), MDP (NOD2 agonist, 100 µM). * p<0.05, ** p<0.01: significantly different from vehicle control (B), or from 50 µM BSA alone (C).

Fig. 2. Polymixin B (LPS sequester) did not affect sodium laurate (C12:0)- or BSA-complexed palmitic acid (C16:0-BSA)-induced COX-2 expression indicating that the induction of COX-2 expression by these fatty acids is not due to LPS contamination in the fatty acid or BSA preparations. RAW 264.7 cells were serum starved in 0.25% FBS/DMEM medium for 6 hr and then pretreated with 10 µg/ml polymixin B for 1 hr followed by coincubation with C12:0, C16:0-BSA, or equivalent concentrations of BSA in the same low serum medium for 18 hr. The protein lysates were probed with anti-COX-2 or anti-β-actin antibody by immunobloting (A, B). Culture medium supernatants were assayed for TNF-α by ELISA (C). Controls: 0.2 ng/ml LPS, 2 ng/ml Pam3CSK4. PM, polymixin B. ** p<0.01: significantly different from no polymix B control (C).
Fig. 3. Sodium laurate (C12:0) or BSA-complexed palmitic acid (C16:0-BSA) induced COX-2 and TNF-α expression in MyD88-/- macrophages, even in the presence of polymixin B eliminating the possibility that the fatty acid effects are due to the potential contaminants in BSA or fatty acid preparations that can activate TLR4 or MyD88-dependent TLRs or IL-1 receptor. MyD88-/- cells were serum starved in 0.25% FBS/DMEM medium for 6 hr and then treated with C12:0, C16:0-BSA, or equivalent concentrations of BSA in the same low serum medium for 18 hr. The protein lysates were probed for COX-2 and β-actin (A), and the culture medium supernatants were assayed for TNF-α (B) as described in Fig 1. Controls: LPS 5 ng/ml, Pam3CSK4 5 ng/ml. ** p<0.01: significantly different from vehicle control, or from 50 µM BSA alone (B).

Fig. 4. Sodium salt of lauric acid (C12:0) or sodium salt of palmitic acid (C16:0) without being complexed with BSA activated the downstream signaling pathways of pattern recognition receptors (PRRs). (A) RAW 264.7 cells were serum starved in 0.25% FBS/DMEM for 6 hr and then treated with 300 µM C12:0 in the same low serum medium for indicated times. (B, C) RAW 264.7 cells were serum starved as in panel A. The cells were then pretreated with indicated concentrations of DHA for 1 hr followed by coincubation with 300 µM C12:0 for 15 min (B) or 100 µM C12:0 for 18 hr (C). (D) THP-1 cells were serum starved in 0.25% FBS/RPMI1640 medium for 12 hr and then treated with 150 µM C16:0 in the same low serum medium for indicated times. Protein lysates from A-D were probed for phosphorylated JNK (JNK-p), JNK, phosphorylated ERK (ERK-p), ERK, phosphorylated IκBα (IκBα-p), IκBα, phosphorylated NFκB p65 (p65-p), NFκB p65 (p65), COX-2 and β-actin by immunobloting. (E, F) THP-1 cells were serum starved as in panel D. The cells were then treated with indicated
concentrations of C16:0 for 24 hr (E) or pretreated with indicated concentrations of DHA for 1 hr and then coincubated with 150 µM C16:0 for 24 hr (F). The resulting culture medium supernatants were assayed for IL-8 by ELISA. ** p<0.01: significantly different from vehicle control (E) or from C16:0 alone (F).

Fig. 5. Sodium laurate (C12:0) or BSA-complexed palmitic acid (C16:0-BSA) induced NFκB activation through TLR2 dimerized with TLR1 or TLR6, and through TLR4. 293T cells were cultured in 10% FBS/DMEM medium and cotransfected with TLR2 and TLR1 (A, D), TLR2 and TLR6 (B, E), TLR4 and MD2 (C, F), in addition to NFκB-luciferase reporter and β-galactosidase expression vectors. After 24 hr, the cells were serum starved in 0.25% FBS/DMEM for 6 hr and then treated with C12:0 (A-C) or C16:0-BSA (D-F) for 12 hr. The cell lysates were assayed for luciferase and galactosidase activities. Values are expressed as RLA (relative luciferase activity). Controls: Pam (PamCSK4, TLR2/1 agonist, 10 ng/ml), MALP-2 (TLR2/6 agonist, 10 ng/ml), LPS (TLR4 agonist, 50 ng/ml). pDisplay empty vector was used as negative controls. * p<0.05, ** p<0.01: significantly different from vehicle control (A-C) or from 50 µM BSA (D-F).

Fig. 6. Sodium laurate (C12:0)-, C16:0-BSA- or TLR agonists-induced COX-2 and TNF-α expression, reactive oxygen species (ROS) production and phosphorylation of JNK and ERK were enhanced in the culture medium with low FBS (0.25%) compared to those with high FBS (10%). (A-C) RAW264.7 cells were serum starved in 0.25% FBS/DMEM medium for 6 hr and then treated with C12:0 (A, C) or C16:0-BSA (B, C) for 16 hr in the same low serum medium or cultured continuously in 10% FBS/DMEM medium and treated with the C12:0 (A,
C) or C16:0-BSA (B, C) for 16 hr. The protein lysates were probed for COX-2 and β–actin by immunobloting (A, B). The culture medium supernatants from vehicle, LPS, 100 µM C12:0, 50 µM BSA and 500 µM C16:0-BSA treatments were assayed for TNF-α by ELISA (C). Controls: 0.2 ng/ml LPS, 2 ng/ml Pam3CSK4 (Pam). (D) RAW264.7 cells were cultured in DMEM medium containing 0.25% or 10% FBS for 6 hr and then treated with vehicle, 0.2 ng/ml LPS, 100 µM C12:0, 50 µM BSA, or 500 µM C16:0-BSA for 16 hr followed by CM-H2DCFDA staining for 30 min. ROS levels were measured by flow cytometry as described in Methods. (E) Summary of the relative ROS production by the treatments in panel D as folds of geometric means. ** p<0.01: significantly different from the value of 10% FBS for vehicle control, LPS, C12:0, BSA and C16:0-BSA treatment samples. (F) RAW 264.7 cells were serum starved in 0.25% FBS/DMEM for 6 hr and then treated with 300 µM C12:0 for indicated times or continuously cultured in 10% FBS/DMEM and treated with 300 µM C12:0 for the same time periods. The protein lysates were probed for phosphorylated JNK (JNK-p), JNK, phosphorylated ERK (ERK-p), ERK and β–actin by immunobloting. Control: 10 ng/ml LPS.

Fig. 7. Enhancement of sodium laurate (C12:0)- or BSA-complexed palmitic acid (C16:0-BSA)-induced JNK or ERK phosphorylation, and COX-2 and TNF-α expression by low serum concentration (0.25% FBS) in the medium was attenuated by NADPH oxidase inhibitor apocynin. (A) RAW264.7 cells were serum starved in 0.25% FBS/DMEM for 6 hr and then treated with 10 µM CM-H2DCFDA for 30 min. followed by treatment with vehicle, 100 ng/ml LPS, 150 µM sodium salt C12:0, 500 µM BSA-complexed C16:0 (C16:0-BSA) or equivalent concentration of BSA for 30 min. ROS levels were analyzed by confocal fluorescent imaging as described in Methods. (B, C) RAW 264.7 cells were serum starved in 0.25%
FBS/DMEM for 6 hr. The cells were then pretreated with indicated concentrations of apocynin (Apo) for 1 hr followed by coincubation with 300 µM C12:0 for 15 min. The protein lysates were probed for JNK-p, JNK, ERK-p, ERK and β-actin by immunobloting. (D-G) RAW 264.7 cells were serum starved as in B, C. The cells were then pretreated with indicated concentrations of apocynin for 1 hr followed by coincubation with 150 µM C12:0 (D, F) or 500 µM C16:0-BSA (E, G) in low 0.25% FBS serum medium for 18 hr. The protein lysates were probed for COX-2 and β-actin by immunobloting (D, E) and the medium supernatants were assayed for TNF-α by ELISA (F, G). 50 µM BSA was used as a control for BSA-complexed C16:0 (C16:0-BSA). * p<0.05, ** p<0.01: significantly different from the C12:0 treated sample without apocynin treatment (F), or C16:0-BSA treated sample without apocynine treatment (G).
Fig. 1A, B

**A**

![Western blot image showing COX-2 and β-actin expression](image)

**B**

![Bar graph showing TNF-α levels](image)
Fig. 1C

C

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>10</th>
<th>30</th>
<th>50</th>
<th>100</th>
<th>300</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>LPS</td>
<td>2500</td>
<td>3000</td>
<td>3500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pam</td>
<td>3000</td>
<td>3500</td>
<td>4000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDP</td>
<td>3500</td>
<td>4000</td>
<td>4500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veh</td>
<td>4000</td>
<td>4500</td>
<td>5000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C16:0 (µM) 10 30 50 10 30 50 BSA (µM)

** * **
Fig. 2

A

<table>
<thead>
<tr>
<th></th>
<th>Veh</th>
<th>LPS</th>
<th>Pam 100</th>
<th>Pam 150</th>
<th>Veh</th>
<th>LPS</th>
<th>Pam 100</th>
<th>Pam 150</th>
</tr>
</thead>
<tbody>
<tr>
<td>C12:0 (μM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veh</td>
<td>300</td>
<td>0</td>
<td>30</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>30</td>
<td>50</td>
</tr>
<tr>
<td>LPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>Pam 100</td>
<td>150</td>
<td>0</td>
<td>30</td>
<td>50</td>
<td>0</td>
<td>300</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>Pam 150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td>500</td>
<td>0</td>
<td>50</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>Veh</th>
<th>LPS</th>
<th>Pam 300</th>
<th>Pam 500</th>
<th>Veh</th>
<th>LPS</th>
<th>Pam 300</th>
<th>Pam 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>C16:0 (μM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veh</td>
<td>300</td>
<td>0</td>
<td>30</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>30</td>
<td>50</td>
</tr>
<tr>
<td>LPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>Pam 300</td>
<td>500</td>
<td>0</td>
<td>30</td>
<td>50</td>
<td>0</td>
<td>300</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>Pam 500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300</td>
<td>500</td>
<td>0</td>
<td>50</td>
</tr>
</tbody>
</table>

- COX-2 ➔
- β-actin ➔
- BSA (μM) ➔
Fig. 2C

C

![Bar graph showing TNF-α levels](chart)

- Veh (0.2 ng/ml)
- LPS (2 ng/ml)
- PAM (100 µM)
- C12:0 (150 µM)
- BSA (50 µM)
- C16:0 (300 µM)
- C16:0 (500 µM)

PM

**
Fig. 3A, B

A MyD88-/-

B MyD88-/-

COX-2

β-actin

Veh

LPS

Pam

C16:0 (µM) C12:0 (µM)

Veh

LPS

Pam

C16:0 (µM) C12:0 (µM)

Veh

LPS

Pam

C16:0 (µM) C12:0 (µM)

Veh

Polymixin B

BSA (µM)

Veh

Polymixin B

TNF-α (pg/ml)

**

**

**

**

**

**

**

MyD88-/-
Fig. 4A-C

A RAW 264.7

C12:0

| Time (min) | Veh | 0 | 2.5 | 5 | 7.5 | 10 | 180 | 180

LPS

0 | 1 | 5 | 10 | 15 | 20 | 25 | 30 | 45 | 60 | 90 | 120 | 180 | 0 | 45

← [JNK-p (p54)]

← [JNK (p54)]

↓ [ERK-p (p44/p42)]

↓ [ERK (p44/p42)]

← [β-actin]

B RAW 264.7

C12:0

Veh | 0 | 2.5 | 5 | 7.5 | DHA (µM)

0 | 1 | 5 | 10 | 180

← [ERK-p (p44/p42)]

← [ERK (p44/p42)]

← [β-actin]

C RAW 264.7

C12:0

Veh | 0 | 2.5 | 5 | 7.5 | 10 | DHA (µM)

0 | 1 | 5 | 10 | 180

← [COX-2]

← [β-actin]
Fig. 4D

D THP-1

<table>
<thead>
<tr>
<th>C16:0</th>
<th>Time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>JNK-p (p54)</td>
</tr>
</tbody>
</table>

by guest, on November 9, 2017www.jlr.org Downloaded from
Fig. 4E, F

E

THP-1

IL-8 (pg/ml)

0 500 1000 1500 2000

Veh - 25 50 100 150 PM

LPS - 25 50 100 150

C16:0 (µM)

F

THP-1

IL-8 pg/ml

0 500 1000 1500

Veh 0 1 2.5 5 7.5 10

DHA (µM)

C16:0

Veh - LPS - LPS +

C16:0 (µM)
Fig. 5A-C

A  TLR2/1

B  TLR2/6

C  TLR4/MD2

RLA (fold)

NFκB Luc

Pam  Veh  25  50  100  Veh  Pam

C12:0 (μM)

Vector

RLA (fold)

NFκB Luc

MALP  Veh  50  100  200  Veh  MALP

C12:0 (μM)

Vector

RLA (fold)

LPS  Veh  50  100  150  Veh  LPS

C12:0 (μM)

Vector
Fig. 5D-F

D  TLR2/1

E  TLR2/6

F  TLR4/MD2

**Fig 5D, E**

**Fig 5F**

Fig. 6A, B, C

A

<table>
<thead>
<tr>
<th></th>
<th>0.25% FBS</th>
<th>10% FBS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C12:0 (μM)</td>
<td>C12:0 (μM)</td>
</tr>
<tr>
<td>Veh</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LPS</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Pam</td>
<td>500</td>
<td>500</td>
</tr>
</tbody>
</table>

**COX-2**

**β-actin**

B

<table>
<thead>
<tr>
<th></th>
<th>0.25% FBS</th>
<th>10% FBS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C16:0 (μM)</td>
<td>C16:0 (μM)</td>
</tr>
<tr>
<td>Veh</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LPS</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Pam</td>
<td>500</td>
<td>500</td>
</tr>
</tbody>
</table>

**COX-2**

**β-actin**

<table>
<thead>
<tr>
<th></th>
<th>0.25% FBS</th>
<th>10% FBS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BSA (μM)</td>
<td></td>
</tr>
<tr>
<td>Veh</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LPS</td>
<td>300</td>
<td>300</td>
</tr>
</tbody>
</table>

**C**

![Graph showing TNF-α (pg/ml) vs. % FBS](image)

**N**

**N**
Fig 6D, E

D

Vehicle

BSA

C12:0

C16:0-BSA

LPS

Counts

$10^0$ $10^1$ $10^2$ $10^3$ $10^4$

FL1-H

E

Relative ROS Production (fold)

% FBS

Veh LPS C12:0 BSA C16:0

0.25 0.25 0.25 0.25 0.25

10% FBS 0.25% FBS

** ** ** **

by guest, on November 9, 2017 www.jlr.org Downloaded from
Fig. 6F

Time (min)

- JNK-p (p54)
- JNK (p54)
- ERK-p (p44/p42)
- ERK (p44/p42)
- β-actin

10% FBS 0.25% FBS
Fig. 7A-E

A

![Image of cellular microscopy with different treatments: Veh (vehicle), LPS, C12:0, Veh, BSA, C16:0-BSA.

B

<table>
<thead>
<tr>
<th>C12:0</th>
<th>Apo (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veh</td>
<td>0.125</td>
</tr>
<tr>
<td>0.25</td>
<td>0.500</td>
</tr>
<tr>
<td>1.00</td>
<td></td>
</tr>
</tbody>
</table>

- JNK-p (p54)
- JNK (p54)
- β-actin

C

<table>
<thead>
<tr>
<th>C12:0</th>
<th>Apo (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veh</td>
<td>0.125</td>
</tr>
<tr>
<td>0.25</td>
<td>0.500</td>
</tr>
<tr>
<td>1.00</td>
<td></td>
</tr>
</tbody>
</table>

- ERK-p (p44/p42)
- ERK (p44/p42)
- β-actin

D

<table>
<thead>
<tr>
<th>C12:0</th>
<th>Apo (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veh</td>
<td>0.125</td>
</tr>
<tr>
<td>0.25</td>
<td>0.500</td>
</tr>
<tr>
<td>1.00</td>
<td></td>
</tr>
</tbody>
</table>

- COX-2
- β-actin

E

<table>
<thead>
<tr>
<th>C16:0-BSA</th>
<th>Apo (mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veh</td>
<td>0.125</td>
</tr>
<tr>
<td>0.250</td>
<td>0.500</td>
</tr>
<tr>
<td>1.000</td>
<td></td>
</tr>
</tbody>
</table>

- COX-2
- β-actin
Fig. 7F, G

F

G

TNF-\( \alpha \) (pg/ml)

Veh
Apo
C12:0

TNF-\( \alpha \) (pg/ml)

Veh
BSA
Apo
C16:0-BSA